Liver Fibrosis Clinical Trial
— HEPSYOfficial title:
Acceptability of Advanced Chronic Liver Disease Screening by Transient Elstography (Fibroscan ®) in Patients Hospitalised in Psychiatric Unit: a Single Center Prospective Study
Scares data exists concerning the prevalence of chronic liver diseases in people with psychiatric disorders. There are still many barriers to screening and linkage to care for patients having somatic illness. Moreover follow-up of these patients may be difficult because of poor access to care, sometimes marginalization, and insufficient compliance with health programs. The aim of this study is to asses acceptability of of advanced chronic liver disease screening by transient elstography (Fibroscan ®) in patients hospitalised in a psychiatric unit.
Status | Not yet recruiting |
Enrollment | 180 |
Est. completion date | December 1, 2024 |
Est. primary completion date | September 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion criteria - adults =18 years - having a psychiatric condition and hospitalized in a psychiatry unit of CHU Montpellier , France - patients who lack capacity of consent if legal representative consents - involuntary psychiatric hospitalization, if consent is given Exclusion criteria - lack of written consent - Unable to understand nature and objective of the methodology - Pregnant or breast feeding woman - Not affiliated with a French social security |
Country | Name | City | State |
---|---|---|---|
France | Montpellier University Hospital | Montpellier |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Montpellier |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | acceptability of non invasive assessement of liver fibrosis by Fibroscan in psychiatric patients | Number of patient who have agreed to do fibroscan screening among patient to whom it was offered. | At Inclusion | |
Secondary | Prevalence of advanced liver disease in psychiatric patients | Number of patient who are diagnosed with advanced liver disease among patient to whom it was offered. | At inclusion | |
Secondary | prevalence of excessive alcohol or drug consumption in psychiatric patients | Number of patient with excessive alcohol/drug consumption | At inclusion | |
Secondary | prevalence of passed or active drug consumption (intraveinous, inhaled or sniffed) in psychiatric patients | Number of patient with excessive alcohol/drug consumption | At Inclusion | |
Secondary | prevalence of viral hepatitis in psychiatric patients | Number of patient diagnosed with viral hepatitis B, D, C | At Inclusion | |
Secondary | correlation between advanced chronic liver diseases and risk factors for liver diseases in psychiatric patients | Number of patients with advanced chronic liver disease among those having risk factors for chronic liver disease | 1 to 3 month after inclusion | |
Secondary | assessment of referral to medical care when advanced fibrosis was diagnosed, regardless of its etiology | Number of patients that have actually came to their medical appoint after advanced fibrosis diagnosis | 1 to 3 month after inclusion | |
Secondary | reason for refusal of non invasive evaluation of chronic liver disease | rate of reasons of refusal according to reason of hospitalization, sector, duration of hospitalization, time spend in study explaination, patient reflection time | At Inclusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06308757 -
Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis
|
N/A | |
Recruiting |
NCT06051669 -
Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US
|
||
Completed |
NCT06244550 -
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors
|
N/A | |
Recruiting |
NCT06098417 -
Biomarkers in the Diagnosis and Prognosis of NAFLD
|
||
Not yet recruiting |
NCT03623360 -
Functional MRI to Determine Severity of Cirrhosis
|
||
Recruiting |
NCT01965418 -
A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial
|
Phase 4 | |
Not yet recruiting |
NCT01133184 -
Improved Prevention of Perinatal Hepatitis B Transmission
|
Phase 4 | |
Completed |
NCT00043303 -
Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis
|
Phase 2 | |
Completed |
NCT03872024 -
Performances Evaluation of New FibroScan Probes Dedicated to Morbidly Obese Patients
|
N/A | |
Recruiting |
NCT05912179 -
Prospective Single Centre Observational Study to Compare the Diagnostic Yield of Different Modalities of Liver Biopsy
|
||
Recruiting |
NCT04533828 -
68Ga-FAPI PET/CT in Liver Fibrosis Patients
|
Early Phase 1 | |
Completed |
NCT04573543 -
The Role of Immune Semaphorins in NAFLD
|
||
Recruiting |
NCT03277651 -
Noninvasive Diagnostic Platform for Liver Fibrosis and Portal Hypertension
|
N/A | |
Completed |
NCT01707472 -
Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis
|
Phase 2 | |
Completed |
NCT01810458 -
Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)
|
||
Completed |
NCT01934777 -
Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis
|
Phase 3 | |
Completed |
NCT01988753 -
Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
|
||
Completed |
NCT02060162 -
Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa
|
||
Completed |
NCT00049842 -
Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)
|
Phase 3 | |
Recruiting |
NCT06063785 -
Multispectral Optoacoustic Tomography in Patients With Cystic Fibrosis
|